BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 7598278)

  • 1. Heparin neutralization by recombinant platelet factor 4 and protamine.
    Levy JH; Cormack JG; Morales A
    Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of heparinase 1 and protamine on platelet reactivity.
    Ammar T; Fisher CF
    Anesthesiology; 1997 Jun; 86(6):1382-6. PubMed ID: 9197309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood.
    Williams RD; D'Ambra MN; Maione TE; Lynch KE; Keene DF
    J Thorac Cardiovasc Surg; 1994 Nov; 108(5):975-83. PubMed ID: 7967683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.
    Cook JJ; Niewiarowski S; Yan Z; Schaffer L; Lu W; Stewart GJ; Mosser DM; Myers JA; Maione TE
    Circulation; 1992 Mar; 85(3):1102-9. PubMed ID: 1537108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass.
    Bernabei A; Gikakis N; Maione TE; Kowalska MA; Yan Z; Niewiarowski S; Edmunds LH
    J Thorac Cardiovasc Surg; 1995 Apr; 109(4):765-71. PubMed ID: 7715225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
    Bode AP; Castellani WJ; Hodges ED; Yelverton S
    Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparinase I (neutralase) reversal of systemic anticoagulation.
    Michelsen LG; Kikura M; Levy JH; Lee MK; Lee KC; Zimmermann JJ; Szlam F
    Anesthesiology; 1996 Aug; 85(2):339-46. PubMed ID: 8712450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass.
    Kikura M; Lee MK; Levy JH
    Anesth Analg; 1996 Aug; 83(2):223-7. PubMed ID: 8694296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
    Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
    Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparinase thromboelastography compared with activated coagulation time for protamine titration after cardiopulmonary bypass.
    Levin AI; Heine AM; Coetzee JF; Coetzee A
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):224-9. PubMed ID: 24461364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin.
    Shanberge JN; Quattrociocchi-Longe TM; Martens MH
    Thromb Res; 1987 Apr; 46(1):89-100. PubMed ID: 3590116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of thromboelastography with heparinase or protamine sulfate added in vitro during heparinized cardiopulmonary bypass.
    Spiess BD; Wall MH; Gillies BS; Fitch JC; Soltow LO; Chandler WL
    Thromb Haemost; 1997 Aug; 78(2):820-6. PubMed ID: 9268178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of viscoelastic coagulation tests during cardiopulmonary bypass.
    Ortmann E; Rubino A; Altemimi B; Collier T; Besser MW; Klein AA
    J Thromb Haemost; 2015 Jul; 13(7):1207-16. PubMed ID: 25903995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.
    Dehmer GJ; Lange RA; Tate DA; Pirwitz M; Daniel W; Fisher M; Bonnem EM
    Circulation; 1996 Nov; 94(9 Suppl):II347-52. PubMed ID: 8901773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density.
    Poon MC; Hurst RE; Rives MS
    Thromb Haemost; 1982 Apr; 47(2):162-5. PubMed ID: 7101237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
    Demma L; Levy JH
    Anesth Analg; 2012 Dec; 115(6):1273-8. PubMed ID: 22859690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.